- Home
- TPG vs ROIV Comparison
TPG vs ROIV Comparison
Compare TPG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- ROIV
- Stock Information
- Founded
- TPG 1992
- ROIV 2014
- Country
- TPG United States
- ROIV United Kingdom
- Employees
- TPG N/A
- ROIV N/A
- Industry
- TPG Investment Managers
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TPG Finance
- ROIV Health Care
- Exchange
- TPG Nasdaq
- ROIV Nasdaq
- Market Cap
- TPG 6.6B
- ROIV 7.8B
- IPO Year
- TPG 2022
- ROIV N/A
- Fundamental
- Price
- TPG $50.55
- ROIV $11.45
- Analyst Decision
- TPG Buy
- ROIV Buy
- Analyst Count
- TPG 13
- ROIV 4
- Target Price
- TPG $62.17
- ROIV $17.50
- AVG Volume (30 Days)
- TPG 1.9M
- ROIV 5.4M
- Earning Date
- TPG 08-05-2025
- ROIV 08-07-2025
- Dividend Yield
- TPG 3.44%
- ROIV N/A
- EPS Growth
- TPG N/A
- ROIV N/A
- EPS
- TPG N/A
- ROIV N/A
- Revenue
- TPG $3,710,887,000.00
- ROIV $29,053,000.00
- Revenue This Year
- TPG N/A
- ROIV $2.64
- Revenue Next Year
- TPG $23.44
- ROIV $378.09
- P/E Ratio
- TPG $16,212.23
- ROIV N/A
- Revenue Growth
- TPG 44.34
- ROIV N/A
- 52 Week Low
- TPG $37.52
- ROIV $8.73
- 52 Week High
- TPG $72.98
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- TPG 55.28
- ROIV 57.83
- Support Level
- TPG $48.67
- ROIV $10.89
- Resistance Level
- TPG $51.56
- ROIV $11.79
- Average True Range (ATR)
- TPG 1.39
- ROIV 0.35
- MACD
- TPG 0.00
- ROIV 0.01
- Stochastic Oscillator
- TPG 73.68
- ROIV 62.57
About TPG TPG Inc.
TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.